High-Throughput Screening Reveals That CeeNU Acts as a New NLRP3 Inflammasome Inhibitor

Area of Science:

• Immunology
• Cell Biology
• Pharmacology

Background:

• Pyroptosis, a form of inflammatory cell death, contributes to tissue damage and disease progression.
• The NLRP3 inflammasome is a key regulator of pyroptosis and inflammatory responses.
• Targeting the NLRP3 inflammasome presents a therapeutic strategy for inflammatory conditions.

Purpose of the Study:

• To identify inhibitors of NLRP3 inflammasome-mediated pyroptosis.
• To investigate the therapeutic potential of FDA-approved drugs for NLRP3-driven diseases.

Main Methods:

• Large-scale drug screening to identify NLRP3 inflammasome inhibitors.
• In vitro studies using human and murine macrophages/microglia to assess pyroptosis inhibition.
• In vivo studies using mouse models of NLRP3 inflammasome-mediated diseases.

Main Results:

• CeeNU was identified as a potent inhibitor of NLRP3 inflammasome activation and pyroptosis.
• CeeNU demonstrated dose-dependent suppression of inflammasome activity and pyroptotic cell death.
• CeeNU specifically binds to NLRP3, blocking its assembly and activation.
• CeeNU provided significant protection in mouse models of EAE, septic shock, peritonitis, and gouty arthritis.

Conclusions:

• CeeNU acts as a specific NLRP3 inflammasome inhibitor.
• CeeNU exhibits therapeutic potential for a range of NLRP3 inflammasome-mediated inflammatory diseases.